论文部分内容阅读
目的探讨二甲双胍与利拉鲁肽联合治疗糖尿病的临床效果。方法选取2016年1月至2017年1月辽阳市中心医院收治的2型糖尿病患者96例为研究对象,均符合糖尿病的诊断标准。回顾性分析患者的一般资料,按照治疗方法不同分为研究组和对照组,研究组患者采用二甲双胍+利拉鲁肽治疗,对照组患者单纯采用二甲双胍治疗。比较两组患者的治疗效果、治疗前后血糖水平变化情况及不良反应发生情况。结果研究组、对照组患者的治疗总有效率分别为95.8%、83.3%,差异有统计学意义(P<0.05);治疗前,两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白水平比较,差异均无统计学意义(均P>0.05);治疗后,两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白水平比较,差异均有统计学意义(均P<0.05);研究组、对照组患者的不良反应发生率分别为4.2%、18.8%,组间比较差异有统计学意义(P<0.05)。结论在糖尿病患者的临床治疗中,给予常规二甲双胍治疗的基础上加用利拉鲁肽,能获得较为理想的效果。
Objective To investigate the clinical efficacy of combination of metformin and liraglutide in the treatment of diabetes mellitus. Methods A total of 96 type 2 diabetic patients admitted from Liaoyang Central Hospital from January 2016 to January 2017 were selected as the research objects, which all met the diagnostic criteria of diabetes. The general data of patients were retrospectively analyzed. According to the different treatment methods, the patients were divided into study group and control group. Metformin plus liraglutide was used in the study group and metformin alone in the control group. The therapeutic effects of two groups were compared, the changes of blood glucose level before and after treatment and the incidence of adverse reactions were compared. Results The total effective rates of the study group and the control group were 95.8% and 83.3%, respectively, with significant difference (P <0.05). Before treatment, fasting blood glucose, postprandial 2-hour postprandial blood glucose and glycosylated hemoglobin (All P> 0.05). After treatment, the fasting blood glucose, postprandial 2-hour postprandial blood glucose and glycosylated hemoglobin were significantly different between the two groups (all P <0.05) The incidence of adverse reactions in the control group was 4.2% and 18.8%, respectively, with significant difference between the two groups (P <0.05). Conclusion In the clinical treatment of diabetic patients, given the conventional metformin treatment based on the addition of liraglutide, to obtain a more satisfactory results.